Clinical Trial

HS-IT201 Injection in the Treatment of Advanced Solid Tumors

Name: HS-IT201 Injection in the Treatment of Advanced Solid Tumors — clinical trial record (NCT06613152)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT201) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor.

Trial Details

NCT Number	NCT06613152
Lead Sponsor	Qingdao Sino-Cell Biomedicine Co., Ltd. Collaborators: The Affiliated Hospital of Qingdao University
Conditions	Solid Tumor
Enrollment	9 participants
Start Date	2024-10
Primary Completion	2026-10 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2024-09-25